Literature DB >> 30575399

Total Synthesis in Search of Potent Antibody-Drug Conjugate Payloads. From the Fundamentals to the Translational.

Kyriacos C Nicolaou1, Stephan Rigol1.   

Abstract

The emergence and evolution of antibody-drug conjugates (ADCs) as targeted cancer therapies in recent years is a living example of the "magic bullet" concept of Paul Ehrlich, introduced by him more than a century ago. Consisting of three components, the antibody serving as the delivery system, the payload drug that kills the cancer cell, and the chemical linker through which the payload is attached to the antibody, ADCs represent a currently hotly pursued paradigm of targeted cancer therapies. While the needed monoclonal antibody falls in the domains of biology and biochemistry, the potent payload and the linker belong to the realm of chemistry. Naturally occurring molecules and their derivatives endowed with high cytotoxic properties have proven to be useful payloads for the first approved ADCs (i.e., Mylotarg, Adcetris, Kadcyla, and Besponsa). The latest approaches and intensifying activities in this new paradigm of cancer therapy demands a variety of payloads with different mechanisms of action in order to address the medical needs for the various types of cancers, challenging synthetic organic chemists to enrich the library of potential payloads. Total synthesis of natural and designed molecules not only provides a powerful avenue to replicate rare naturally occurring compounds in the laboratory but also offers a unique opportunity to rationally design and synthesize analogues thereof for biological evaluation and optimization of ADC payloads. In this Account, we describe our efforts in this area highlighting a number of total synthesis endeavors through which we rendered scarce naturally occurring molecules readily available for biological evaluations and, most importantly, employed the developed synthetic strategies and methods to construct, otherwise unavailable or difficult to reach, designed analogues of these molecules. Specifically, we summarize the total syntheses of natural and designed molecules of the calicheamicin, uncialamycin, tubulysin, trioxacarcin, epothilone, shishijimicin, namenamicin, thailanstatin, and disorazole families of compounds and demonstrate how these studies led to the discovery of analogues of higher potencies, yet some of them possessing lower complexities than their parent compounds as potential ADC payloads. The highlighted examples showcase the continuing impact of total synthesis of natural products and their analogues on modern medicine, including the so-called biologics and should prove useful and inspirational in advancing both the fields of total synthesis and biomedical research and the drug discovery and development process.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30575399     DOI: 10.1021/acs.accounts.8b00537

Source DB:  PubMed          Journal:  Acc Chem Res        ISSN: 0001-4842            Impact factor:   22.384


  6 in total

1.  Perspectives from nearly five decades of total synthesis of natural products and their analogues for biology and medicine.

Authors:  K C Nicolaou; Stephan Rigol
Journal:  Nat Prod Rep       Date:  2020-04-22       Impact factor: 13.423

Review 2.  New Technologies Bloom Together for Bettering Cancer Drug Conjugates.

Authors:  Yiming Jin; Shahab Edalatian Zakeri; Raman Bahal; Andrew J Wiemer
Journal:  Pharmacol Rev       Date:  2022-07       Impact factor: 18.923

3.  Yangpumicins F and G, Enediyne Congeners from Micromonospora yangpuensis DSM 45577.

Authors:  Zilong Wang; Zhongqing Wen; Ling Liu; Xiangcheng Zhu; Ben Shen; Xiaohui Yan; Yanwen Duan; Yong Huang
Journal:  J Nat Prod       Date:  2019-09-06       Impact factor: 4.050

Review 4.  Antibody-Drug Conjugates Containing Payloads from Marine Origin.

Authors:  Iván Cheng-Sánchez; Federico Moya-Utrera; Cristina Porras-Alcalá; Juan M López-Romero; Francisco Sarabia
Journal:  Mar Drugs       Date:  2022-07-30       Impact factor: 6.085

5.  Photoactivatable prodrug for simultaneous release of mertansine and CO along with a BODIPY derivative as a luminescent marker in mitochondria: a proof of concept for NIR image-guided cancer therapy.

Authors:  Rajeshwari Tiwari; Prashant S Shinde; Sreejesh Sreedharan; Anik Kumar Dey; Katherine A Vallis; Santosh B Mhaske; Sumit Kumar Pramanik; Amitava Das
Journal:  Chem Sci       Date:  2020-12-23       Impact factor: 9.825

Review 6.  The promising role of antibody drug conjugate in cancer therapy: Combining targeting ability with cytotoxicity effectively.

Authors:  Wen-Qian Li; Han-Fei Guo; Ling-Yu Li; Yong-Fei Zhang; Jiu-Wei Cui
Journal:  Cancer Med       Date:  2021-06-24       Impact factor: 4.452

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.